Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) has been assigned a consensus rating of “Hold” from the twelve analysts that are covering the stock, MarketBeat.com reports. Eight investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $78.22.
TPTX has been the topic of a number of recent research reports. Wedbush lowered shares of Turning Point Therapeutics from an “outperform” rating to a “neutral” rating and boosted their price target for the stock from $61.00 to $76.00 in a research report on Friday, June 3rd. Cowen lowered shares of Turning Point Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, June 6th. Cowen lowered shares of Turning Point Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, June 6th. Guggenheim set a $76.00 target price on shares of Turning Point Therapeutics in a report on Monday, June 20th. Finally, Wells Fargo & Company lowered shares of Turning Point Therapeutics from an “overweight” rating to an “equal weight” rating and set a $76.00 target price on the stock. in a report on Friday, June 3rd.
In other news, CFO Paolo Tombesi sold 1,183 shares of the business’s stock in a transaction that occurred on Wednesday, July 27th. The shares were sold at an average price of $74.94, for a total value of $88,654.02. Following the sale, the chief financial officer now directly owns 28,700 shares of the company’s stock, valued at approximately $2,150,778. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 8.60% of the company’s stock.
Institutional Investors Weigh In On Turning Point Therapeutics
Turning Point Therapeutics Stock Up 0.7 %
TPTX stock opened at $76.01 on Monday. The stock has a market capitalization of $3.81 billion, a P/E ratio of -11.02 and a beta of -0.18. The firm has a 50-day simple moving average of $75.49 and a 200-day simple moving average of $54.27. Turning Point Therapeutics has a 52 week low of $23.77 and a 52 week high of $82.20.
Turning Point Therapeutics (NASDAQ:TPTX – Get Rating) last posted its quarterly earnings results on Monday, August 8th. The company reported ($2.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.78) by ($0.70). The company had revenue of $0.12 million for the quarter, compared to analysts’ expectations of $2.27 million. The company’s revenue was down 97.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.14) EPS. On average, analysts expect that Turning Point Therapeutics will post -7.69 earnings per share for the current year.
Turning Point Therapeutics Company Profile
Turning Point Therapeutics, Inc, a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.
- Get a free copy of the StockNews.com research report on Turning Point Therapeutics (TPTX)
- Kroger’s is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.